Credits: Canva
The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.
It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.
The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.
In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.
TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."
Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.
While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.
Credit: PIB
Union Health Minister JP Nadda has announced the launch of cervical cancer screenings using Visual Inspection with Acetic Acid (VIA) are now available at Ayushman Arogya Mandirs and other health facilities for women between 30 and 65 years of age.
"Screening for cervical cancer is now available at 1,81,000 Ayushman Arogya Mandirs, also known as Health and Wellness Centers, across the country as a part of population based screening for early detection and treatment," said Nadda, while addressing a press briefing at the World Health Organization virtually.
Using VIA, a low-cost, point-of-care method, trained health workers will screen women for cervical cancer. Those who test positive will then be referred to higher centers for diagnostic confirmation and further evaluation.
Nadda also shared that the cervical cancer screening in the country has been expanded as part of comprehensive primary healthcare under the National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD).
"Over 86 million women have already been screened for cervical cancer under the program, reflecting India’s sustained commitment to early detection and prevention," Nadda informed.
Despite being highly preventable as well as treatable, cervical cancer is a public health concern in India.
The country loses one women every eight minutes to cervical cancer.
As per the World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, about 42,000 new cases of cervical cancer is reported annually in India. This underscores the need for preventive measures such as vaccination and early screening.
The WHO Global Strategy to eliminate cervical cancer includes the 90-70-90 targets by 2030 -- vaccinating 90 per cent of girls against HPV, screening 70 percent of women, and ensuring treatment for 90 percent of those diagnosed with cervical disease.
In line with the global strategy to fight cervical cancer, Prime Minister Narendra Modi recently also launched a free HPV vaccination drive that will target health and well being of adolescent girls in the country.
Cervical cancer develops in a women's cervix (uterus opening) due to abnormal cell growth, primarily caused by persistent HPV infection, a common infection that's passed through sexual contact.
When exposed to HPV, the body's immune system typically prevents the virus from causing damage however, in a small percentage of people, the virus can survive for years and pave the way for some cervical cells to become cancerous.
Treatment involves surgery, radiation, and chemotherapy, with early detection significantly improving outcomes, though it remains a major cancer in low-income countries Cervical cancer can also be prevented through vaccination and regular screening (Pap/HPV tests).
Cervical cancer has no symptoms in the early days and therefore, is hard to detect until it has spread. However, the early-stage symptoms include:
How Can Cervical Cancer Be Prevented?
Cervical cancer is largely preventable and, when detected early, it is highly treatable. The WHO recommends HPV vaccination for girls aged 9 to 14, before they become sexually active, along with regular cervical screening from age 30, or 25 for women living with HIV.
Despite this, unequal access to vaccination, screening and treatment continues to drive higher rates of illness and deaths in regions such as sub-Saharan Africa, Central America and Southeast Asia.
Credit: PIB
Union Health Minister JP Nadda has announced the launch of cervical cancer screenings using Visual Inspection with Acetic Acid (VIA) are now available at Ayushman Arogya Mandirs and other health facilities for women between 30 and 65 years of age.
"Screening for cervical cancer is now available at 1,81,000 Ayushman Arogya Mandirs, also known as Health and Wellness Centers, across the country as a part of population based screening for early detection and treatment," said Nadda, while addressing a press briefing at the World Health Organization virtually.
Using VIA, a low-cost, point-of-care method, trained health workers will screen women for cervical cancer. Those who test positive will then be referred to higher centers for diagnostic confirmation and further evaluation.
Nadda also shared that the cervical cancer screening in the country has been expanded as part of comprehensive primary healthcare under the National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD).
"Over 86 million women have already been screened for cervical cancer under the program, reflecting India’s sustained commitment to early detection and prevention," Nadda informed.
Despite being highly preventable as well as treatable, cervical cancer is a public health concern in India.
The country loses one women every eight minutes to cervical cancer.
As per the World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, about 42,000 new cases of cervical cancer is reported annually in India. This underscores the need for preventive measures such as vaccination and early screening.
The WHO Global Strategy to eliminate cervical cancer includes the 90-70-90 targets by 2030 -- vaccinating 90 per cent of girls against HPV, screening 70 percent of women, and ensuring treatment for 90 percent of those diagnosed with cervical disease.
In line with the global strategy to fight cervical cancer, Prime Minister Narendra Modi recently also launched a free HPV vaccination drive that will target health and well being of adolescent girls in the country.
Cervical cancer develops in a women's cervix (uterus opening) due to abnormal cell growth, primarily caused by persistent HPV infection, a common infection that's passed through sexual contact.
When exposed to HPV, the body's immune system typically prevents the virus from causing damage however, in a small percentage of people, the virus can survive for years and pave the way for some cervical cells to become cancerous.
Treatment involves surgery, radiation, and chemotherapy, with early detection significantly improving outcomes, though it remains a major cancer in low-income countries Cervical cancer can also be prevented through vaccination and regular screening (Pap/HPV tests).
Cervical cancer has no symptoms in the early days and therefore, is hard to detect until it has spread. However, the early-stage symptoms include:
How Can Cervical Cancer Be Prevented?
Cervical cancer is largely preventable and, when detected early, it is highly treatable. The WHO recommends HPV vaccination for girls aged 9 to 14, before they become sexually active, along with regular cervical screening from age 30, or 25 for women living with HIV.
Despite this, unequal access to vaccination, screening and treatment continues to drive higher rates of illness and deaths in regions such as sub-Saharan Africa, Central America and Southeast Asia.
Japan has confirmed an outbreak of HPAI (Highly Pathogenic Avian Influenza) at a poultry farm, media reports said.
The avian flu, confirmed in Hokkaido in the northern prefecture, marks the fourth case and the country's 21st outbreak this season, Xinhua news agency reported.
The Ministry of Agriculture, Forestry and Fisheries, in a statement, said that the affected farm is located in the town of Abira, and keeps about 190,000 chickens.
The farm notified local health officials earlier this week, who rapidly followed up with a rapid avian influenza test.
The positive result was confirmed by genetic testing the following day.
“All chickens at the farm will be culled, incinerated, and buried to prevent further spread of the virus,” the authorities said.
Previously, the HPAI outbreak at a poultry farm in Iwate prefecture was reported in February.
Jiji Press reported that the outbreak in the town of Kanegasaki led to the culling of about 560,000 egg-laying hens at the affected farm.
The bird flu season in Japan typically runs from autumn until the following spring.
HPAI is a classification for bird-flu viruses that cause severe disease and high mortality in poultry, and also spreads rapidly.
The influenza A H5N1 virus is one of the most common viruses that cause HPAI.
Others include
Outbreaks of HPAI, especially H5N1, continue in wild birds and poultry worldwide, with active disease zones being reported.
While authorities are culling birds, no human cases have been reported.
Recent detections include the first confirmed HPAI infections in marine mammals (northern elephant seals) in California -- the first such reported cases in 2026.
Suspected HPAI cases have triggered poultry culls and control measures in the UK and Northern Ireland.
Europe reported multiple outbreaks on commercial poultry farms.
According to the World Health Organization, there have been about 994 confirmed human infections reported worldwide since 2003.
This virus does not appear to transmit easily from person to person, and sustained human-to-human transmission has not been reported.
© 2024 Bennett, Coleman & Company Limited